

LIST OF TABLES

List of Tables

- Table 1: Cytomegalovirus (HHV-5) Infections Therapeutics Market, Global, Clinical Trials by Zone, 2013*
- Table 2: Cytomegalovirus (HHV-5) Infections Therapeutics Market, Global, Clinical Trials by Top Countries, 2013*
- Table 3: Cytomegalovirus (HHV-5) Infections Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013*
- Table 4: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2013*
- Table 5: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2013*
- Table 6: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, North America, Top Countries, 2013*
- Table 7: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2013*
- Table 8: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Central and South America, Top Countries, 2013*
- Table 9: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, BRIC Countries, 2013*
- Table 10: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, G7 Countries, 2013*
- Table 11: Cytomegalovirus (HHV-5) Infections Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2013*
- Table 12: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, E7 Countries, 2013*
- Table 13: Cytomegalovirus (HHV-5) Infections Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2013*
- Table 14: Cytomegalovirus (HHV-5) Infections Therapeutics Market, Global, Clinical Trials by Phase, 2013*
- Table 15: Cytomegalovirus (HHV-5) Infections Therapeutics Market, Global, Clinical Trials In Progress by Phase 2013*
- Table 16: Cytomegalovirus (HHV-5) Infections Therapeutics Market, Global, Clinical Trials by Trial Status, 2013*
- Table 17: Cytomegalovirus (HHV-5) Infections Therapeutics Market, Global, Withdrawn Clinical Trials, 2013*
- Table 18: Cytomegalovirus (HHV-5) Infections Therapeutics Market, Global, Terminated Clinical Trials, 2013*
- Table 19: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2007-2012
- Table 20: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2013*

Table 21: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2013*

Table 22: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2013*

Table 23: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2013*

Table 24: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Hoffmann-La Roche Inc., 2013*

Table 25: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by ViroPharma Incorporated, 2013*

Table 26: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2013*

Table 27: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2013*

Table 28: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Vical Incorporated, 2013*

Table 29: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Isis Pharmaceuticals, Inc., 2013*

Table 30: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Chimerix, Inc., 2013*

Table 31: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Gilead Sciences, Inc., 2013*

Table 32: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Theraclone Sciences, Inc., 2013*

Table 33: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Genentech, Inc., 2013*

Table 34: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2013*

Table 35: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Cell Medica Limited, 2013*

Table 36: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by AiCuris GmbH & Co. KG, 2013*

Table 37: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Roche Global Development, 2013*

Table 38: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by AlphaVax, Inc., 2013*

Table 39: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Sandoz Inc., 2013*

Table 40: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Astellas Pharma Inc., 2013*

Table 41: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2013*

Table 42: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2013*

Table 43: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2013*

Table 44: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2013*

Table 45: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by National Eye Institute, 2013*

Table 46: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Baylor College of Medicine, 2013*

Table 47: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by National Center for Research Resources, 2013*

Table 48: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2013*

Table 49: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Hadassah Medical Organization, 2013*

Table 50: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2013*

Table 51: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Alabama at Birmingham, 2013*

Table 52: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2013*

Table 53: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Kobe University, 2013*

Table 54: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital, Limoges, 2013*

Table 55: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2013*

Table 56: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by City of Hope National Medical Center, 2013*

Table 57: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Hospital do Rim e Hipertensao, 2013*

Table 58: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2013*

Table 59: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2013*

Table 60: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2013*

Table 61: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Charles University, 2013*

Table 62: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pennsylvania, 2013*

Table 63: Clinical Trial Product Information - A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients

Table 64: Clinical Trial Details - A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients

Table 65: Drug Details - A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients

Table 66: Patient Details - A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients

Table 67: Trial Results - A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients

Table 68: Investigators Information - A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients

Table 69: Location(s)/Sponsor(s) - A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients

Table 70: Location (s) - Details (82) - A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients

Table 71: Clinical Trial Product Information - A Phase II/III Study of the Safety and Efficacy of 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl) Cytosine Dihydrate (Cidofovir; HPMPC) for the Treatment of Peripheral Cytomegalovirus Retinitis in Patients with AIDS

Table 72: Clinical Trial Details - A Phase II/III Study of the Safety and Efficacy of 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl) Cytosine Dihydrate (Cidofovir; HPMPC) for the Treatment of Peripheral Cytomegalovirus Retinitis in Patients with AIDS

Table 73: Drug Details - A Phase II/III Study of the Safety and Efficacy of 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl) Cytosine Dihydrate (Cidofovir; HPMPC) for the Treatment of Peripheral Cytomegalovirus Retinitis in Patients with AIDS

Table 74: Patient Details - A Phase II/III Study of the Safety and Efficacy of 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl) Cytosine Dihydrate (Cidofovir;

HPMPC) for the Treatment of Peripheral Cytomegalovirus Retinitis in Patients with AIDS

Table 75: Trial Results - A Phase II/III Study of the Safety and Efficacy of 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl) Cytosine Dihydrate (Cidofovir; HPMPC) for the Treatment of Peripheral Cytomegalovirus Retinitis in Patients with AIDS

Table 76: Investigators Information - A Phase II/III Study of the Safety and Efficacy of 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl) Cytosine Dihydrate (Cidofovir; HPMPC) for the Treatment of Peripheral Cytomegalovirus Retinitis in Patients with AIDS

Table 77: Location(s)/Sponsor(s) - A Phase II/III Study of the Safety and Efficacy of 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl) Cytosine Dihydrate (Cidofovir; HPMPC) for the Treatment of Peripheral Cytomegalovirus Retinitis in Patients with AIDS

Table 78: Location (s) - Details (9) - A Phase II/III Study of the Safety and Efficacy of 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl) Cytosine Dihydrate (Cidofovir; HPMPC) for the Treatment of Peripheral Cytomegalovirus Retinitis in Patients with AIDS

Table 79: Contact Detail(s) - A Phase II/III Study of the Safety and Efficacy of 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl) Cytosine Dihydrate (Cidofovir; HPMPC) for the Treatment of Peripheral Cytomegalovirus Retinitis in Patients with AIDS

Table 80: Clinical Trial Product Information - A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients with Advanced HIV Infection (100 CD4+ Lymphocytes)

Table 81: Clinical Trial Details - A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients with Advanced HIV Infection (100 CD4+ Lymphocytes)

Table 82: Drug Details - A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients with Advanced HIV Infection (100 CD4+ Lymphocytes)

Table 83: Patient Details - A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients with Advanced HIV Infection (100 CD4+ Lymphocytes)

Table 84: Trial Results - A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients with Advanced HIV Infection (100 CD4+ Lymphocytes)

Table 85: Investigators Information - A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients with Advanced HIV Infection (100 CD4+ Lymphocytes)

Table 86: Location(s)/Sponsor(s) - A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients with Advanced HIV Infection (100 CD4+ Lymphocytes)

Table 87: Location (s) - Details (35) - A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients with Advanced HIV Infection (100 CD4+ Lymphocytes)

Table 88: Contact Detail(s) - Details (35) - A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients with Advanced HIV Infection (100 CD4+ Lymphocytes)

Table 89: Clinical Trial Product Information - A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS

Table 90: Clinical Trial Details - A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS

Table 91: Drug Details - A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS

Table 92: Patient Details - A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS

Table 93: Trial Results - A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS

Table 94: Investigators Information - A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS

Table 95: Location(s)/Sponsor(s) - A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS

Table 96: Location (s) - Details (23) - A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS

Table 97: Contact Detail(s) - A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS

Table 98: Clinical Trial Product Information - A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

Table 99: Clinical Trial Details - A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

Table 100: Drug Details - A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

Table 101: Patient Details - A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes
Table 102: Trial Results - A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes
Table 103: Investigators Information - A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes
Table 104: Location(s)/Sponsor(s) - A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes
Table 105: Location (s) - Details (19) - A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes
Table 106: Contact Detail(s) - A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

List of Figures

Figure 1: Cytomegalovirus (HHV-5) Infections Therapeutics Market, Global, Clinical Trials by Zone (%), 2013*
Figure 2: Cytomegalovirus (HHV-5) Infections Therapeutics Market, Global, Clinical Trials by Top Countries, 2013*
Figure 3: Cytomegalovirus (HHV-5) Infections Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013*
Figure 4: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2013*
Figure 5: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2013*
Figure 6: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2013*
Figure 7: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2013*
Figure 8: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, BRIC Countries (%), 2013*
Figure 9: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, G7 Countries (%), 2013*
Figure 10: Cytomegalovirus (HHV-5) Infections Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2013*
Figure 11: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, E7 Countries (%), 2013*
Figure 12: Cytomegalovirus (HHV-5) Infections Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2013*
Figure 13: Cytomegalovirus (HHV-5) Infections Therapeutics Market, Global, Clinical Trials by Phase (%), 2013*
Figure 14: Cytomegalovirus (HHV-5) Infections Therapeutics Market, Global, Clinical Trials In Progress by Phase, 2013*
Figure 15: Cytomegalovirus (HHV-5) Infections Therapeutics Market, Global, Clinical Trials by Trial Status, 2013*
Figure 16: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2007-2012

Figure 17: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2013*

Figure 18: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2013*

Figure 19: Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2013*

Figure 20: GlobalData Methodology